OCTOBER 05, 2017 LONDON, Oct. 5, 2017 /PRNewswire/ — Bio-Techne has been selected as a supplier of research antibodies under Lot 1: Antibodies of the Southern Universities Purchasing Consortium (SUPC), Antibodies and Sera Framework Agreement for the United Kingdom (UK) Higher Education Sector. The Framework serves 6 major UK-based academic consortia across England, Scotland and Wales... Read more
SAN JOSE, Calif., Sept. 20, 2017 /PRNewswire/ — ProteinSimple®, a Bio-Techne brand, announced today an expansion of the Ella immunoassay platform with the launch of a 32×4 Simple Plex™ cartridge. This new cartridge simultaneously measures up to 32 different samples from serum, plasma, cell culture supernatants and other bodily fluids against four different analytes of interest. Doubling... Read more
MINNEAPOLIS, Sept. 6, 2017 /PRNewswire/ — R&D Systems®, a Bio-Techne brand, announced today the release of a new rapid, solid phase, enzyme-linked immunosorbent assay (ELISA) designed to measure anti-Zika virus immunoglobulin G (IgG) antibodies in human serum. A unique feature of this assay is that, prior to performing the test, samples are pre-treated with a proprietary... Read more
SEPTEMBER 05, 2017 MINNEAPOLIS, Sept. 5, 2017 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today that it has acquired all of the stock of Trevigen Inc. for cash. The transaction is financed through available cash on hand. Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne, commented, “We are pleased to have Trevigen as... Read more
MINNEAPOLIS, Minnesota (March 7, 2017)- Bio-Techne has entered into an exclusive license agreement with Multiclonal Therapeutics (MCT) to commercialize reagents and media systems in the research reagent field intended for cloning, propagating, and differentiating adult “ground-state” stem cells from healthy and diseased epithelial tissues. Working together, Bio-Techne and MCT will transition this breakthrough technology into... Read more
WASHINGTON, D.C. MINNEAPOLIS, MN – January 9, 2017 – The COPD Foundation-sponsored COPD Biomarker Qualification Consortium (CBQC) today announced that it has partnered with the Bio-Techne Corporation, a manufacturer of biotechnology products for life science research and diagnostics. The partnership was established to evaluate the suitability of a soluble form of receptor for advanced glycation... Read more